FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:RBP4-GPC3

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: RBP4-GPC3
FusionPDB ID: 73063
FusionGDB2.0 ID: 73063
HgeneTgene
Gene symbol

RBP4

GPC3

Gene ID

5950

2719

Gene nameretinol binding protein 4glypican 3
SynonymsMCOPCB10|RDCCASDGSX|GTR2-2|MXR7|OCI-5|SDYS|SGB|SGBS|SGBS1
Cytomap

10q23.33

Xq26.2

Type of geneprotein-codingprotein-coding
Descriptionretinol-binding protein 4PRBPRBPplasma retinol-binding proteinretinol binding protein 4, plasmaretinol-binding protein 4, interstitialglypican-3glypican proteoglycan 3heparan sulphate proteoglycanintestinal protein OCI-5secreted glypican-3
Modification date2020031320200315
UniProtAcc.

P51654

Main function of 5'-partner protein: FUNCTION: Cell surface proteoglycan that bears heparan sulfate (PubMed:14610063). Negatively regulates the hedgehog signaling pathway when attached via the GPI-anchor to the cell surface by competing with the hedgehog receptor PTC1 for binding to hedgehog proteins (By similarity). Binding to the hedgehog protein SHH triggers internalization of the complex by endocytosis and its subsequent lysosomal degradation (By similarity). Positively regulates the canonical Wnt signaling pathway by binding to the Wnt receptor Frizzled and stimulating the binding of the Frizzled receptor to Wnt ligands (PubMed:16227623, PubMed:24496449). Positively regulates the non-canonical Wnt signaling pathway (By similarity). Binds to CD81 which decreases the availability of free CD81 for binding to the transcriptional repressor HHEX, resulting in nuclear translocation of HHEX and transcriptional repression (By similarity). Inhibits the dipeptidyl peptidase activity of DPP4 (PubMed:17549790). Plays a role in limb patterning and skeletal development by controlling the cellular response to BMP4 (By similarity). Modulates the effects of growth factors BMP2, BMP7 and FGF7 on renal branching morphogenesis (By similarity). Required for coronary vascular development (By similarity). Plays a role in regulating cell movements during gastrulation (By similarity). {ECO:0000250|UniProtKB:Q6V9Y8, ECO:0000250|UniProtKB:Q8CFZ4, ECO:0000269|PubMed:14610063, ECO:0000269|PubMed:16227623, ECO:0000269|PubMed:17549790, ECO:0000269|PubMed:24496449}.
Ensembl transtripts involved in fusion geneENST idsENST00000371464, ENST00000371467, 
ENST00000371469, 
ENST00000370818, 
ENST00000394299, ENST00000543339, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score4 X 4 X 3=4812 X 11 X 6=792
# samples 412
** MAII scorelog2(4/48*10)=-0.263034405833794
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(12/792*10)=-2.72246602447109
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: RBP4 [Title/Abstract] AND GPC3 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: RBP4 [Title/Abstract] AND GPC3 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)RBP4(95360150)-GPC3(132670321), # samples:1
Anticipated loss of major functional domain due to fusion event.RBP4-GPC3 seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF.
RBP4-GPC3 seems lost the major protein functional domain in Tgene partner, which is a cell metabolism gene due to the frame-shifted ORF.
RBP4-GPC3 seems lost the major protein functional domain in Tgene partner, which is a CGC due to the frame-shifted ORF.
RBP4-GPC3 seems lost the major protein functional domain in Tgene partner, which is a IUPHAR drug target due to the frame-shifted ORF.
RBP4-GPC3 seems lost the major protein functional domain in Tgene partner, which is a tumor suppressor due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneRBP4

GO:0030277

maintenance of gastrointestinal epithelium

10944490

HgeneRBP4

GO:0032526

response to retinoic acid

571335

HgeneRBP4

GO:0042593

glucose homeostasis

17003346

TgeneGPC3

GO:0060828

regulation of canonical Wnt signaling pathway

14610063

TgeneGPC3

GO:0090263

positive regulation of canonical Wnt signaling pathway

24496449

TgeneGPC3

GO:2000050

regulation of non-canonical Wnt signaling pathway

14610063



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr10:95360150/chrX:132670321)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across RBP4 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across GPC3 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000371464RBP4chr1095360150-ENST00000543339GPC3chrX132670321-59942932598189
ENST00000371467RBP4chr1095360150-ENST00000370818GPC3chrX132670321-1224675859137240
ENST00000371467RBP4chr1095360150-ENST00000394299GPC3chrX132670321-1215675859137240
ENST00000371469RBP4chr1095360150-ENST00000370818GPC3chrX132670321-9263775611187
ENST00000371469RBP4chr1095360150-ENST00000394299GPC3chrX132670321-9173775611187

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000371464ENST00000543339RBP4chr1095360150-GPC3chrX132670321-0.0040182610.9959817
ENST00000371467ENST00000370818RBP4chr1095360150-GPC3chrX132670321-0.0026306870.9973693
ENST00000371467ENST00000394299RBP4chr1095360150-GPC3chrX132670321-0.0025721030.9974279
ENST00000371469ENST00000370818RBP4chr1095360150-GPC3chrX132670321-0.0017144430.9982856
ENST00000371469ENST00000394299RBP4chr1095360150-GPC3chrX132670321-0.0016412660.99835867

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for RBP4-GPC3

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
RBP4chr1095360150GPC3chrX132670321429133KYWGVASFLQKGKLAYDLDVDDAPGN

Top

Potential FusionNeoAntigen Information of RBP4-GPC3 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
RBP4-GPC3_95360150_132670321.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:01LQKGKLAY0.99990.8459816
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:25LQKGKLAY0.99750.8951816
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:03LQKGKLAY0.95090.7414816
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:01FLQKGKLAY0.99960.8791716
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:25FLQKGKLAY0.9930.9268716
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:02FLQKGKLAY0.9850.9384716
RBP4-GPC3chr1095360150chrX132670321429HLA-B35:08FLQKGKLAY0.91340.9239716
RBP4-GPC3chr1095360150chrX132670321429HLA-B35:01FLQKGKLAY0.83690.9363716
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:03FLQKGKLAY0.74650.7833716
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:18FLQKGKLAY0.63460.7419716
RBP4-GPC3chr1095360150chrX132670321429HLA-B35:05FLQKGKLAY0.62520.7352716
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:01SFLQKGKLAY0.98410.9166616
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:25SFLQKGKLAY0.94270.938616
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:02SFLQKGKLAY0.93150.9496616
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:01ASFLQKGKLAY0.99890.9076516
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:25ASFLQKGKLAY0.99860.9387516
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:17ASFLQKGKLAY0.99850.9377516
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:07LQKGKLAY0.99970.6913816
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:04LQKGKLAY0.99950.8834816
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:07FLQKGKLAY0.99880.7562716
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:21FLQKGKLAY0.98140.9207716
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:04FLQKGKLAY0.93060.9039716
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:05FLQKGKLAY0.92220.9154716
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:31FLQKGKLAY0.86850.9204716
RBP4-GPC3chr1095360150chrX132670321429HLA-C03:14FLQKGKLAY0.10680.9882716
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:07SFLQKGKLAY0.95310.8394616
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:21SFLQKGKLAY0.93670.9255616
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:05SFLQKGKLAY0.82470.9113616
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:07ASFLQKGKLAY0.99870.8457516
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:27LQKGKLAY0.99990.8808816
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:135LQKGKLAY0.99990.8657816
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:34LQKGKLAY0.99990.8459816
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:50LQKGKLAY0.99990.9183816
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:33LQKGKLAY0.99990.8459816
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:125LQKGKLAY0.99990.8459816
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:35LQKGKLAY0.99970.8775816
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:12LQKGKLAY0.99950.8508816
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:53LQKGKLAY0.99950.8327816
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:54LQKGKLAY0.99880.7879816
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:39LQKGKLAY0.99780.8013816
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:68LQKGKLAY0.9960.5614816
RBP4-GPC3chr1095360150chrX132670321429HLA-B35:28LQKGKLAY0.95130.9565816
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:34FLQKGKLAY0.99960.8791716
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:125FLQKGKLAY0.99960.8791716
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:50FLQKGKLAY0.99960.931716
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:27FLQKGKLAY0.99960.9182716
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:33FLQKGKLAY0.99960.8791716
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:135FLQKGKLAY0.99950.8997716
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:12FLQKGKLAY0.99910.8052716
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:11FLQKGKLAY0.99910.8387716
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:35FLQKGKLAY0.99890.9155716
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:08FLQKGKLAY0.99890.8482716
RBP4-GPC3chr1095360150chrX132670321429HLA-B35:43FLQKGKLAY0.99860.8441716
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:24FLQKGKLAY0.9980.9359716
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:53FLQKGKLAY0.99530.8709716
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:39FLQKGKLAY0.99330.8395716
RBP4-GPC3chr1095360150chrX132670321429HLA-B35:11FLQKGKLAY0.97810.9154716
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:54FLQKGKLAY0.93950.8301716
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:20FLQKGKLAY0.92410.9581716
RBP4-GPC3chr1095360150chrX132670321429HLA-B35:28FLQKGKLAY0.88260.961716
RBP4-GPC3chr1095360150chrX132670321429HLA-B35:20FLQKGKLAY0.85040.9658716
RBP4-GPC3chr1095360150chrX132670321429HLA-B35:23FLQKGKLAY0.83880.9442716
RBP4-GPC3chr1095360150chrX132670321429HLA-B35:77FLQKGKLAY0.83690.9363716
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:13FLQKGKLAY0.77880.7112716
RBP4-GPC3chr1095360150chrX132670321429HLA-C12:02FLQKGKLAY0.74580.9772716
RBP4-GPC3chr1095360150chrX132670321429HLA-B35:30FLQKGKLAY0.65030.8473716
RBP4-GPC3chr1095360150chrX132670321429HLA-B35:17FLQKGKLAY0.65030.8473716
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:68FLQKGKLAY0.62580.6247716
RBP4-GPC3chr1095360150chrX132670321429HLA-C07:17FLQKGKLAY0.55020.9761716
RBP4-GPC3chr1095360150chrX132670321429HLA-B35:24FLQKGKLAY0.50430.9045716
RBP4-GPC3chr1095360150chrX132670321429HLA-C14:03FLQKGKLAY0.35140.9693716
RBP4-GPC3chr1095360150chrX132670321429HLA-C14:02FLQKGKLAY0.35140.9693716
RBP4-GPC3chr1095360150chrX132670321429HLA-C03:02FLQKGKLAY0.34780.9593716
RBP4-GPC3chr1095360150chrX132670321429HLA-B18:04FLQKGKLAY0.33870.9496716
RBP4-GPC3chr1095360150chrX132670321429HLA-B48:02FLQKGKLAY0.23780.9505716
RBP4-GPC3chr1095360150chrX132670321429HLA-B18:07FLQKGKLAY0.14620.8976716
RBP4-GPC3chr1095360150chrX132670321429HLA-C02:02FLQKGKLAY0.06490.9795716
RBP4-GPC3chr1095360150chrX132670321429HLA-C02:10FLQKGKLAY0.06490.9795716
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:50SFLQKGKLAY0.98630.9537616
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:125SFLQKGKLAY0.98410.9166616
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:34SFLQKGKLAY0.98410.9166616
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:33SFLQKGKLAY0.98410.9166616
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:27SFLQKGKLAY0.98380.9465616
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:12SFLQKGKLAY0.98360.8248616
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:135SFLQKGKLAY0.98140.9283616
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:35SFLQKGKLAY0.95020.9355616
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:39SFLQKGKLAY0.94510.8655616
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:20SFLQKGKLAY0.82510.9479616
RBP4-GPC3chr1095360150chrX132670321429HLA-C14:02SFLQKGKLAY0.33550.9684616
RBP4-GPC3chr1095360150chrX132670321429HLA-C14:03SFLQKGKLAY0.33550.9684616
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:39ASFLQKGKLAY0.9990.8552516
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:125ASFLQKGKLAY0.99890.9076516
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:34ASFLQKGKLAY0.99890.9076516
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:33ASFLQKGKLAY0.99890.9076516
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:135ASFLQKGKLAY0.99880.9123516
RBP4-GPC3chr1095360150chrX132670321429HLA-B15:35ASFLQKGKLAY0.99860.9409516
RBP4-GPC3chr1095360150chrX132670321429HLA-B58:06ASFLQKGKLAY0.99650.8886516

Top

Potential FusionNeoAntigen Information of RBP4-GPC3 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
RBP4-GPC3_95360150_132670321.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
RBP4-GPC3chr1095360150chrX132670321429DRB1-0409KGKLAYDLDVDDAPG1025
RBP4-GPC3chr1095360150chrX132670321429DRB1-0409QKGKLAYDLDVDDAP924
RBP4-GPC3chr1095360150chrX132670321429DRB1-0462KGKLAYDLDVDDAPG1025
RBP4-GPC3chr1095360150chrX132670321429DRB1-0467KGKLAYDLDVDDAPG1025
RBP4-GPC3chr1095360150chrX132670321429DRB1-0467QKGKLAYDLDVDDAP924
RBP4-GPC3chr1095360150chrX132670321429DRB1-1111VASFLQKGKLAYDLD419
RBP4-GPC3chr1095360150chrX132670321429DRB1-1114VASFLQKGKLAYDLD419
RBP4-GPC3chr1095360150chrX132670321429DRB1-1114GVASFLQKGKLAYDL318
RBP4-GPC3chr1095360150chrX132670321429DRB1-1114WGVASFLQKGKLAYD217
RBP4-GPC3chr1095360150chrX132670321429DRB1-1114ASFLQKGKLAYDLDV520
RBP4-GPC3chr1095360150chrX132670321429DRB1-1120VASFLQKGKLAYDLD419
RBP4-GPC3chr1095360150chrX132670321429DRB1-1120GVASFLQKGKLAYDL318
RBP4-GPC3chr1095360150chrX132670321429DRB1-1120WGVASFLQKGKLAYD217
RBP4-GPC3chr1095360150chrX132670321429DRB1-1120ASFLQKGKLAYDLDV520
RBP4-GPC3chr1095360150chrX132670321429DRB1-1168VASFLQKGKLAYDLD419
RBP4-GPC3chr1095360150chrX132670321429DRB1-1168GVASFLQKGKLAYDL318
RBP4-GPC3chr1095360150chrX132670321429DRB1-1168WGVASFLQKGKLAYD217
RBP4-GPC3chr1095360150chrX132670321429DRB1-1186VASFLQKGKLAYDLD419
RBP4-GPC3chr1095360150chrX132670321429DRB1-1186GVASFLQKGKLAYDL318
RBP4-GPC3chr1095360150chrX132670321429DRB1-1186WGVASFLQKGKLAYD217
RBP4-GPC3chr1095360150chrX132670321429DRB1-1302VASFLQKGKLAYDLD419
RBP4-GPC3chr1095360150chrX132670321429DRB1-1302GVASFLQKGKLAYDL318
RBP4-GPC3chr1095360150chrX132670321429DRB1-1302WGVASFLQKGKLAYD217
RBP4-GPC3chr1095360150chrX132670321429DRB1-1302ASFLQKGKLAYDLDV520
RBP4-GPC3chr1095360150chrX132670321429DRB1-1316VASFLQKGKLAYDLD419
RBP4-GPC3chr1095360150chrX132670321429DRB1-1316GVASFLQKGKLAYDL318
RBP4-GPC3chr1095360150chrX132670321429DRB1-1316WGVASFLQKGKLAYD217
RBP4-GPC3chr1095360150chrX132670321429DRB1-1323VASFLQKGKLAYDLD419
RBP4-GPC3chr1095360150chrX132670321429DRB1-1323GVASFLQKGKLAYDL318
RBP4-GPC3chr1095360150chrX132670321429DRB1-1323WGVASFLQKGKLAYD217
RBP4-GPC3chr1095360150chrX132670321429DRB1-1323ASFLQKGKLAYDLDV520
RBP4-GPC3chr1095360150chrX132670321429DRB1-1329VASFLQKGKLAYDLD419
RBP4-GPC3chr1095360150chrX132670321429DRB1-1329GVASFLQKGKLAYDL318
RBP4-GPC3chr1095360150chrX132670321429DRB1-1329WGVASFLQKGKLAYD217
RBP4-GPC3chr1095360150chrX132670321429DRB1-1331VASFLQKGKLAYDLD419
RBP4-GPC3chr1095360150chrX132670321429DRB1-1334VASFLQKGKLAYDLD419
RBP4-GPC3chr1095360150chrX132670321429DRB1-1334GVASFLQKGKLAYDL318
RBP4-GPC3chr1095360150chrX132670321429DRB1-1334WGVASFLQKGKLAYD217
RBP4-GPC3chr1095360150chrX132670321429DRB1-1334ASFLQKGKLAYDLDV520
RBP4-GPC3chr1095360150chrX132670321429DRB1-1336VASFLQKGKLAYDLD419
RBP4-GPC3chr1095360150chrX132670321429DRB1-1339VASFLQKGKLAYDLD419
RBP4-GPC3chr1095360150chrX132670321429DRB1-1339GVASFLQKGKLAYDL318
RBP4-GPC3chr1095360150chrX132670321429DRB1-1339WGVASFLQKGKLAYD217
RBP4-GPC3chr1095360150chrX132670321429DRB1-1339ASFLQKGKLAYDLDV520
RBP4-GPC3chr1095360150chrX132670321429DRB1-1341VASFLQKGKLAYDLD419
RBP4-GPC3chr1095360150chrX132670321429DRB1-1341GVASFLQKGKLAYDL318
RBP4-GPC3chr1095360150chrX132670321429DRB1-1363VASFLQKGKLAYDLD419
RBP4-GPC3chr1095360150chrX132670321429DRB1-1373VASFLQKGKLAYDLD419
RBP4-GPC3chr1095360150chrX132670321429DRB1-1373GVASFLQKGKLAYDL318
RBP4-GPC3chr1095360150chrX132670321429DRB1-1373WGVASFLQKGKLAYD217
RBP4-GPC3chr1095360150chrX132670321429DRB1-1373ASFLQKGKLAYDLDV520
RBP4-GPC3chr1095360150chrX132670321429DRB1-1374VASFLQKGKLAYDLD419
RBP4-GPC3chr1095360150chrX132670321429DRB1-1374GVASFLQKGKLAYDL318
RBP4-GPC3chr1095360150chrX132670321429DRB1-1374WGVASFLQKGKLAYD217
RBP4-GPC3chr1095360150chrX132670321429DRB1-1374ASFLQKGKLAYDLDV520
RBP4-GPC3chr1095360150chrX132670321429DRB1-1396VASFLQKGKLAYDLD419
RBP4-GPC3chr1095360150chrX132670321429DRB1-1396GVASFLQKGKLAYDL318
RBP4-GPC3chr1095360150chrX132670321429DRB1-1397VASFLQKGKLAYDLD419
RBP4-GPC3chr1095360150chrX132670321429DRB1-1397GVASFLQKGKLAYDL318
RBP4-GPC3chr1095360150chrX132670321429DRB1-1397WGVASFLQKGKLAYD217
RBP4-GPC3chr1095360150chrX132670321429DRB1-1397ASFLQKGKLAYDLDV520
RBP4-GPC3chr1095360150chrX132670321429DRB1-1399VASFLQKGKLAYDLD419
RBP4-GPC3chr1095360150chrX132670321429DRB1-1399GVASFLQKGKLAYDL318
RBP4-GPC3chr1095360150chrX132670321429DRB1-1399WGVASFLQKGKLAYD217
RBP4-GPC3chr1095360150chrX132670321429DRB1-1399ASFLQKGKLAYDLDV520

Top

Fusion breakpoint peptide structures of RBP4-GPC3

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
8555SFLQKGKLAYDLDVRBP4GPC3chr1095360150chrX132670321429

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of RBP4-GPC3

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN8555SFLQKGKLAYDLDV-5.49577-5.60917
HLA-B14:023BVN8555SFLQKGKLAYDLDV-4.37152-5.40682
HLA-B52:013W398555SFLQKGKLAYDLDV-6.90336-7.01676
HLA-B52:013W398555SFLQKGKLAYDLDV-4.80833-5.84363
HLA-A11:014UQ28555SFLQKGKLAYDLDV-9.82261-9.93601
HLA-A24:025HGA8555SFLQKGKLAYDLDV-9.78612-9.89952
HLA-A24:025HGA8555SFLQKGKLAYDLDV-4.98992-6.02522
HLA-B27:056PYJ8555SFLQKGKLAYDLDV-5.31553-6.35083
HLA-B44:053DX88555SFLQKGKLAYDLDV-5.70582-5.81922
HLA-B44:053DX88555SFLQKGKLAYDLDV-4.32241-5.35771

Top

Vaccine Design for the FusionNeoAntigens of RBP4-GPC3

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
RBP4-GPC3chr1095360150chrX132670321516ASFLQKGKLAYTAGCCTCCTTTCTCCAGAAAGGAAAACTGGCCT
RBP4-GPC3chr1095360150chrX132670321616SFLQKGKLAYCCTCCTTTCTCCAGAAAGGAAAACTGGCCT
RBP4-GPC3chr1095360150chrX132670321716FLQKGKLAYCCTTTCTCCAGAAAGGAAAACTGGCCT
RBP4-GPC3chr1095360150chrX132670321816LQKGKLAYTTCTCCAGAAAGGAAAACTGGCCT

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
RBP4-GPC3chr1095360150chrX1326703211025KGKLAYDLDVDDAPGAGAAAGGAAAACTGGCCTATGATCTGGATGTGGATGATGCGCCTG
RBP4-GPC3chr1095360150chrX132670321217WGVASFLQKGKLAYDACTGGGGCGTAGCCTCCTTTCTCCAGAAAGGAAAACTGGCCTATG
RBP4-GPC3chr1095360150chrX132670321318GVASFLQKGKLAYDLGGGGCGTAGCCTCCTTTCTCCAGAAAGGAAAACTGGCCTATGATC
RBP4-GPC3chr1095360150chrX132670321419VASFLQKGKLAYDLDGCGTAGCCTCCTTTCTCCAGAAAGGAAAACTGGCCTATGATCTGG
RBP4-GPC3chr1095360150chrX132670321520ASFLQKGKLAYDLDVTAGCCTCCTTTCTCCAGAAAGGAAAACTGGCCTATGATCTGGATG
RBP4-GPC3chr1095360150chrX132670321924QKGKLAYDLDVDDAPTCCAGAAAGGAAAACTGGCCTATGATCTGGATGTGGATGATGCGC

Top

Information of the samples that have these potential fusion neoantigens of RBP4-GPC3

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
LIHCRBP4-GPC3chr1095360150ENST00000371464chrX132670321ENST00000543339TCGA-BW-A5NO-01A

Top

Potential target of CAR-T therapy development for RBP4-GPC3

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to RBP4-GPC3

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to RBP4-GPC3

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource